Cassava Sciences | PTIE - Pre Tax Profit


Cassava Sciences reported $-10.81M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Eisai JPY 22B 7.47B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Geron USD -31.14M 12.72M Dec/2025
J&J USD 7.82B 2.86B Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Roche Holding CHF 4.79B 3.01B Jun/2025